Search for amniotic fluid-specific markers: Novel biomarker candidates for amniotic fluid embolism

Open Women's Health Journal

Volumn 5, Issue 1, 2011, Pages 7-15

  Kobayashi, Hiroshi ^a   Naruse, Katsuhiko ^a   Sado, Toshiyuki ^a   Noguchi, Taketoshi ^a   Yoshida, Shozo ^a   Shigetomi, Hiroshi ^a   Onogi, Akira ^a   Oi, Hidekazu ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Amniotic fluid embolism; Biomarker; Proteomics; Squamous cell carcinoma antigen

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; COPROPORPHYRIN; INTERLEUKIN 6; SOMATOMEDIN BINDING PROTEIN 1; SQUAMOUS CELL CARCINOMA ANTIGEN; TRYPTASE; UNCLASSIFIED DRUG; ZINC COPROPORPHYRIN 1;

AMNION FLUID EMBOLISM; COMPLEMENT ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEOMICS; REVIEW;

EID: 84858975072     PISSN: None     EISSN: 18742912     Source Type: Journal    
DOI: 10.2174/1874291201105010007     Document Type: Review

References (69)

1. Tsangaris G, Weitzdörfer R, Pollak D, Lubec G, Fountoulakis M. The amniotic fluid cell proteome. Electrophoresis 2005; 26: 1168-73.
2. Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol 2008; 199: 49.e1-8.
3. De Jong MJ, Fausett MB. Anaphylactoid syndrome of pregnancy: a devastating complication requiring intensive care. Crit Care Nurse 2003; 23: 42-8.
4. Vascotto C, Salzano AM, D'Ambrosio C, et al. Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia. J Proteome Res 2007; 6: 160-70.
5. Thadikkaran L, Crettaz D, Siegenthaler MA, et al. The role of proteomics in the assessment of premature rupture of fetal membranes. Clin Chim Acta 2005; 360: 27-36.
6. Hassan MI, Kumar V, Singh TP, Yadav S. Proteomic analysis of human amniotic fluid from Rh(-) pregnancy. Prenat Diagn 2008; 28: 102-8.
7. Michel PE, Crettaz D, Morier P, et al. Proteome analysis of human plasma and amniotic fluid by Off-Gel isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 2006; 27: 1169-81.
8. Gravett MG, Novy MJ, Rosenfeld RG, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004; 292: 462-9.
9. Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics 2000; 1: 395-416.
10. Hampton T. Comprehensive proteomic profile of amniotic fluid may aid prenatal diagnosis. JAMA 2007; 298: 1751
11. Oi H, Kobayashi H, Hirashima Y, Yamazaki T, Kobayashi T, Terao T. Serological and immunohistochemical diagnosis of amniotic fluid embolism. Semin Thromb Hemost 1998; 24: 479-84.
12. Kanayama N, Yamazaki T, Naruse H, Sumimoto K, Horiuchi K, Terao T. Determining zinc coproporphyrin in maternal plasma--a new method for diagnosing amniotic fluid embolism. Clin Chem 1992; 38: 526-9.
13. Takeshima N, Suminami Y, Takeda O, Abe H, Kato H. Origin of CA125 and SCC antigen in human amniotic fluid. Asia Oceania J Obstet Gynaecol 1993;19:199-204.
14. Sarandakou A, Kontoravdis A, Kontogeorgi Z, Rizos D, Phocas I. Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 44: 215-20.
15. Usta IM, Sibai BM, Mercer BM, Kreamer BL, Gourley GR. Use of maternal plasma level of zinc-coproporphyrin in the prediction of intrauterine passage of meconium: a pilot study. J Matern Fetal Med 2000; 9: 201-3.
16. Kobayashi H, Ohi H, Terao T. A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc. Am J Obstet Gynecol 1993; 168: 848-53.
17. Oi H, Naruse K, Noguchi T, et al. Fatal factors of clinical manifestations and laboratory testing in patients with amniotic fluid embolism. Gynecol Obstet Invest 2010; 70(2): 138-44.
18. Kobayashi H, Ooi H, Hayakawa H, et al. Histological diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc epitope. Hum Pathol 1997; 28: 428-33.
19. Van Cortenbosch B, Huel C, Houfflin Debarge V, et al. Biologic tests for the diagnosis of amniotic fluid embolism. Ann Biol Clin (Paris) 2007; 65: 153-60.
20. Leong AS, Norman JE, Smith R. Vascular and myometrial changes in the human uterus at term. Reprod Sci 2008; 15: 59-65.
21. Benson MD. Nonfatal amniotic fluid embolism: three possible cases and a new clinical definition. Arch Fam Med 1993; 2: 989-94.
22. Benson MD, Lindberg RE. Amniotic fluid embolism, anaphylaxis, and tryptase. Am J Obstet Gynecol 1996; 175 (3 Part 1): 737.
23. Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. Med Hypotheses 2007; 68: 1019-25.
24. Fineschi V, Gambassi R, Gherardi M, Turillazzi E. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. Int J Legal Med 1998; 111: 238-43.
25. Nishio H, Matsui K, Miyazaki T, Tamura A, Iwata M, Suzuki K. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Sci Int 2002; 126: 53-6.
26. Farrar SC, Gherman RB. Serum tryptase analysis in a woman with amniotic fluid embolism: a case report. J Reprod Med 2001; 46: 926-8.
27. Rainio J, Penttila A. Amniotic fluid embolism as cause of death in a car accident a case report. Forensic Sci Int 2003; 137: 231-4.
28. Benson MD, Kobayashi H, Silver RK, Oi H, Greenberger PA, Terao T. Immunologic studies in presumed amniotic fluid embolism. Obstet Gynecol 2001; 97: 510-4.
29. Dorne R, Pommier C, Emery JC, Dieudonne F, Bongiovanni JP. Amniotic fluid embolism: successful evolution course after uterine arteries embolization. Ann Fr Anesth Reanim 2002; 21: 431-5.
30. Fineschi V, Riezzo I, Cantatore S, Pomara C, Turillazzi E, Neri M. Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism. Virchows Arch 2009; 454: 283-90.
31. Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin Dev Immunol. 2012; 2012: 946576.
32. Suminami Y, Nawata S, Kato H. Biological role of SCC antigen. Tumour Biol 1998; 19: 488-93.
33. Sarandakou A, Rizos D, Botsis D, et al. Mucin-like carcinoma-associated antigen (MCA) during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 96: 51-4.
34. Melegos DN, Yu H, Allen LC, Diamandis EP. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 1996; 29: 555-62.
35. Inaba N, Fukasawa I, Okajima Y, et al. Immunoradiometrical measurement of tissue polypeptide specific antigen (TPS) in normal, healthy, nonpregnant and pregnant Japanese women. Asia Oceania J Obstet Gynaecol 1993; 19: 459-66.
36. Beardsley DI, Kowbel D, Lataxes TA, et al. Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Exp Cell Res 2003; 290: 402-13.
37. Khosravi J, Krishna RG, Bodani U, et al. Immunoassay of serine-phosphorylated isoform of insulin-like growth factor (IGF) binding protein (IGFBP)-1. Clin Biochem 2007; 40: 86-93.
38. Qu X, Yang M, Zhang W, et al. Osteopontin expression in human decidua is associated with decidual natural killer cells recruitment and regulated by progesterone. In vivo 2008; 22: 55-61.
39. Gaucherand P, Salle B, Sergeant P, et al. Comparative study of three vaginal markers of the premature rupture of membranes. Insulin like growth factor binding protein 1 diamine-oxidase pH. Acta Obstet Gynecol Scand 1997; 76: 536-40.
40. Ye F, Cayre YE, Thang MN. Evidence for a novel RasGAP-associated protein of 105 kDa in both mature trophoblasts and differentiating choriocarcinoma cells. Biochem Biophys Res Commun 1999; 263: 523-7.
41. Lorenzen JA, Bonacci BB, Palmer RE, et al. Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. Gene Expr Patterns 2005; 6: 45-56.
42. Ind TE, Iles RK, Wathen NC, Carvalho C, Campbell J, Chard T. Second trimester amniotic fluid placental alkaline phosphatase levels are low in Down's syndrome but not in other fetal abnormalities. Early Hum Dev 1994; 37: 39-44.
43. John CD, Christian HC, Morris JF, Flower RJ, Solito E, Buckingham JC. Annexin 1 and the regulation of endocrine function. Trends Endocrinol Metab 2004; 15: 103-9.
44. Orum O, Hansen M, Jensen CH, et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996; 19: 157-63.
45. Mock P, Frydman R, Bellet D, et al. Expression of pro-EPIL peptides encoded by the insulin-like 4 (INSL4) gene in chromosomally abnormal pregnancies. J Clin Endocrinol Metab 2000; 85: 3941-4.
46. Furuhashi N, Kimura H, Nagae H, Yajima A, Kimura C, Saito T. Brain natriuretic peptide and atrial natriuretic peptide levels in normal pregnancy and preeclampsia. Gynecol Obstet Invest 1994; 38: 73-7.
47. Raffin-Sanson ML, Ferré F, Coste J, Oliver C, Cabrol D, Bertagna X. Pro-opiomelanocortin in human pregnancy: evolution of maternal plasma levels, concentrations in cord blood, amniotic fluid and at the feto-maternal interface. Eur J Endocrinol 2000; 142: 53-9.
48. Syversen U, Opsjøn SL, Stridsberg M, et al. Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies. J Clin Endocrinol Metab 1996; 81: 4470-5.
49. Menon R, Camargo MC, Thorsen P, Lombardi SJ, Fortunato SJ. Amniotic fluid interleukin-6 increase is an indicator of spontaneous preterm birth in white but not black Americans. Am J Obstet Gynecol 2008; 198: 77.e1-7.
50. Torbé A, Czajka R, Kordek A, Rzepka R, Kwiatkowski S, Rudnicki J. Maternal serum proinflammatory cytokines in preterm labor with intact membranes: neonatal outcome and histological associations. Eur Cytokine Netw 2007; 18: 102-7.
51. Holst RM, Laurini R, Jacobsson B, et al. Expression of cytokines and chemokines in cervical and amniotic fluid: relationship to histological chorioamnionitis. J Matern Fetal Neonatal Med 2007; 20: 885-93.
52. Menon R, Williams SM, Fortunato SJ. Amniotic fluid interleukin-1beta and interleukin-8 concentrations: racial disparity in preterm birth. Reprod Sci 2007; 14: 253-9.
53. Menon R, Thorsen P, Vogel I, et al. Racial disparity in amniotic fluid concentrations of tumor necrosis factor (TNF)-alpha and soluble TNF receptors in spontaneous preterm birth. Am J Obstet Gynecol 2008; 198: 533 e1-533.
54. Williams MA, Farrand A, Mittendorf R, et al. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999; 149: 323-9.
55. Rooney IA, Morgan BP. Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 1992; 76: 541-7.
56. Abele R, Tampé R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004; 19: 216-24.
57. Yamaguchi Y, Passeron T, Hoashi T, et al. Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes. FASEB J 2008; 22: 1009-20.
58. Kierszenbaum AL. Polycystins: what polycystic kidney disease tells us about sperm. Mol Reprod Dev 2004; 67: 385-8.
59. Krupa FG, Faltin D, Cecatti JG, Surita FG, Souza JP. Predictors of preterm birth. Int J Gynaecol Obstet 2006; 94: 5-11.
60. Yurchenco PD, Amenta PS, Patton BL. Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol 2004; 22: 521-38.
61. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000; 20: 2902-6.
62. Conlon I, Raff M. Size control in animal development. Cell 1999; 96: 235-44.
63. Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv 2003; 58: 804-26.
64. Demir N, Celiloglu M, Thomassen PA, Onvural A, Erten O. Maternal, fetal and amniotic fluid prolactin levels in term and post- term pregnancies. Acta Obstet Gynecol Scand 1993; 72: 218-20.
65. Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta super-family expression and actions in the endometrium and placenta. Reproduction 2006; 132: 217-32.
66. Florio P, Lambert-Messerlian G, Severi FM, Buonocore G, Canick JA, Petraglia F. Fetal neural tube defects: maternal serum and amniotic fluid activin A levels. Prenat Diagn 2004; 24: 574-5.
67. Porstmann T, Wietschke R, Cobet G, et al. Immunochemical quantification of Cu/Zn superoxide dismutase in prenatal diagnosis of Down's syndrome. Hum Genet 1990; 85: 362-6.
68. Ognibene A, Ciuti R, Tozzi P, Messeri G. Maternal serum superoxide dismutase (SOD): a possible marker for screening Down syndrome affected pregnancies. Prenat Diagn 1999; 19: 1058-60.
69. Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 2000; 1482: 65-72.